Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Monday, up 8.35% from the previous trading day, before settling in for the closing price of $40.85. Over the past 52 weeks, MLYS has traded in a range of $8.24-$47.65.
A company in the Healthcare sector has dropped its sales by -170.42% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 31.01%. With a float of $56.39 million, this company’s outstanding shares have now reached $78.97 million.
Mineralys Therapeutics Inc (MLYS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 28.74%, while institutional ownership is 79.54%. The most recent insider transaction that took place on Nov 11 ’25, was worth 5,363,716. In this transaction CFO and Secretary of this company sold 119,524 shares at a rate of $44.88, taking the stock ownership to the 19,396 shares. Before that another transaction happened on Nov 11 ’25, when Company’s Chief Executive Officer sold 200,000 for $45.44, making the entire transaction worth $9,088,499. This insider now owns 631,305 shares in total.
Mineralys Therapeutics Inc (MLYS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.98 earnings per share (EPS), higher than consensus estimate (set at -1.08) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.76% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 25.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -2.38 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Let’s dig in a bit further. During the last 5-days, its volume was 3.15 million. That was better than the volume of 1.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 65.67%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 90.33%, which indicates a significant increase from 75.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.78 in the past 14 days, which was higher than the 1.88 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.34, while its 200-day Moving Average is $20.84. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $46.39. Second resistance stands at $48.52. The third major resistance level sits at $51.42. If the price goes on to break the first support level at $41.35, it is likely to go to the next support level at $38.45. The third support level lies at $36.32 if the price breaches the second support level.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 3.50 billion has total of 79,140K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -43,270 K.
